Arie Belldegrun
Co-Founder and Chairman @ Bellco Capital
Los Angeles, United States
Arie Belldegrun is a Series A investor at Bellco Capital in Los Angeles focused on Biotechnology and Medical. Arie Belldegrun is the Co-Founder and Chairman of Bellco Capital, a Co-Chairman at Breakthrough Properties, an Executive Chairman and Co-Founder at Allogene Therapeutics, the Founder, Chairman, President, and CEO of Kite Pharma, and the Chairman and Partner at Two River. He attended Hadassah Medical School and Harvard Medical School.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Arie Belldegrun invests in
Stages Arie Belldegrun invests in
Countries Arie Belldegrun invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (83%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Baby 1 (17%)
- Chemical 1 (17%)
Stage
- Series A 3 (50%)
- Series C 1 (17%)
- Debt Financing 1 (17%)
- Post-IPO Equity 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / Series C / May 13, 2024 | |
|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $70M / Series A / Apr 15, 2020 | |
Kronos Bio
|
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology inorder to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling. | $105M / Series A / Jul 18, 2019 | |
Allogene Therapeutics
|
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing andadvanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. | $411.8M / Series A / Apr 19, 2018 | |
Arno Therapeutics
|
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. | $8M / Post-IPO Equity / Aug 16, 2016 | |
Kite Pharma
|
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potentialtherapies could provide novel strategies for the treatment and management of a wide range of tumor types. | $50M / Debt Financing / May 02, 2014 |
Co-Investors
About Bellco Capital
Bellco Capital is a private equity firm based in Los Angeles, California.
Bellco Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Arie Belldegrun
Co-Founder and Chairman
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arie Belldegrun invest in?
Arie Belldegrun invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Arie Belldegrun?
Public channels for Arie Belldegrun include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Arie Belldegrun last invest?
The most recent investment recorded for Arie Belldegrun closed in May 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
